cefepime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 535 88040-23-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefepime dihydrochloride hydrate
  • cefepime
  • cefepime hydrochloride
  • cefimen
  • tsefepim
  • cefepime HCl
A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.
  • Molecular weight: 480.56
  • Formula: C19H24N6O5S2
  • CLOGP: -4.87
  • LIPINSKI: 1
  • HAC: 11
  • HDO: 2
  • TPSA: 150.04
  • ALOGS: -4.49
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 85 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.28 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.78 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 18, 1996 FDA HOSPIRA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 404.19 19.03 287 15052 105258 56171470
Encephalopathy 399.40 19.03 194 15145 35131 56241597
Acute kidney injury 304.27 19.03 350 14989 240413 56036315
Neurotoxicity 222.32 19.03 101 15238 15694 56261034
Status epilepticus 201.11 19.03 93 15246 15048 56261680
Sepsis 162.28 19.03 195 15144 139645 56137083
Drug reaction with eosinophilia and systemic symptoms 155.44 19.03 99 15240 30205 56246523
Cytokine release syndrome 151.30 19.03 69 15270 10806 56265922
Pyrexia 141.50 19.03 335 15004 418438 55858290
Multiple organ dysfunction syndrome 140.90 19.03 116 15223 52654 56224074
Myoclonus 140.74 19.03 73 15266 15130 56261598
Septic shock 122.70 19.03 114 15225 60721 56216007
Thrombocytopenia 115.81 19.03 163 15176 136061 56140667
Respiratory failure 101.14 19.03 127 15212 94935 56181793
Mental status changes 99.15 19.03 82 15257 37419 56239309
Pain 97.59 19.03 30 15309 663154 55613574
Toxic encephalopathy 93.20 19.03 41 15298 5897 56270831
Acute generalised exanthematous pustulosis 93.09 19.03 48 15291 9821 56266907
Tubulointerstitial nephritis 91.84 19.03 57 15282 16608 56260120
Pneumonia 88.33 19.03 277 15062 406821 55869907
Rheumatoid arthritis 84.39 19.03 5 15334 382599 55894129
Arthralgia 74.94 19.03 22 15317 501647 55775081
Klebsiella infection 71.07 19.03 37 15302 7719 56269009
Clostridium difficile colitis 69.25 19.03 50 15289 18688 56258040
Fatigue 65.93 19.03 71 15268 788481 55488247
Alopecia 64.17 19.03 4 15335 293454 55983274
Neutropenia 62.52 19.03 135 15204 158032 56118696
Neutrophil count decreased 61.81 19.03 72 15267 49750 56226978
Platelet count decreased 59.32 19.03 105 15234 106278 56170450
Pathogen resistance 58.95 19.03 30 15309 5970 56270758
Hypoxia 58.86 19.03 73 15266 53824 56222904
Bacteraemia 58.43 19.03 42 15297 15589 56261139
Abdominal discomfort 57.14 19.03 5 15334 277269 55999459
Renal tubular necrosis 57.04 19.03 36 15303 10792 56265936
Immune effector cell-associated neurotoxicity syndrome 56.87 19.03 20 15319 1588 56275140
Drug resistance 56.54 19.03 46 15293 20496 56256232
Mixed liver injury 48.55 19.03 23 15316 3921 56272807
Drug intolerance 46.70 19.03 8 15331 264810 56011918
Cytomegalovirus test positive 45.92 19.03 20 15319 2806 56273922
Acute respiratory distress syndrome 45.92 19.03 42 15297 21884 56254844
Nasopharyngitis 45.47 19.03 4 15335 220955 56055773
Headache 44.77 19.03 52 15287 558992 55717736
Fungaemia 44.46 19.03 18 15321 2106 56274622
Aspartate aminotransferase increased 42.80 19.03 79 15260 82523 56194205
Malaise 40.71 19.03 25 15314 367835 55908893
Hypotension 40.62 19.03 155 15184 250353 56026375
Renal impairment 39.09 19.03 75 15264 80638 56196090
Shock 38.60 19.03 38 15301 21690 56255038
Clostridium difficile infection 38.31 19.03 42 15297 27156 56249572
Respiratory distress 37.99 19.03 45 15294 31622 56245106
Cholestatic liver injury 36.80 19.03 16 15323 2236 56274492
Nephropathy toxic 36.74 19.03 25 15314 8502 56268226
Renal failure 36.60 19.03 88 15251 110412 56166316
Pancytopenia 36.47 19.03 77 15262 88638 56188090
Dizziness 35.81 19.03 30 15309 376110 55900618
Enterococcal infection 35.64 19.03 23 15316 7161 56269567
Systemic lupus erythematosus 35.11 19.03 4 15335 180074 56096654
Therapeutic product effect decreased 35.03 19.03 3 15336 169449 56107279
Product dose omission issue 34.34 19.03 7 15332 204746 56071982
Antibiotic level above therapeutic 34.34 19.03 9 15330 261 56276467
Acute respiratory failure 33.85 19.03 42 15297 30952 56245776
Peripheral swelling 33.69 19.03 11 15328 234715 56042013
Nephritis allergic 33.64 19.03 8 15331 154 56276574
Trichosporon infection 33.64 19.03 9 15330 283 56276445
Blood creatinine increased 33.42 19.03 70 15269 80121 56196607
Hepatic function abnormal 33.29 19.03 44 15295 34514 56242214
Differentiation syndrome 33.14 19.03 12 15327 1037 56275691
Swelling 33.09 19.03 12 15327 239759 56036969
Confusional state 33.07 19.03 128 15211 208027 56068701
Pseudomonas infection 33.00 19.03 25 15314 10046 56266682
Rash maculo-papular 32.91 19.03 40 15299 28867 56247861
Toxic epidermal necrolysis 32.72 19.03 35 15304 22007 56254721
Weight decreased 31.64 19.03 13 15326 240701 56036027
Metabolic encephalopathy 31.48 19.03 19 15320 5261 56271467
Alanine aminotransferase increased 31.45 19.03 75 15264 93587 56183141
Sinusitis 30.66 19.03 8 15331 197573 56079155
Anaemia 30.61 19.03 149 15190 267362 56009366
Mucormycosis 30.58 19.03 15 15324 2759 56273969
Encephalitis Japanese B 30.42 19.03 6 15333 45 56276683
Bronchopulmonary aspergillosis 30.41 19.03 22 15317 8242 56268486
Enterococcal bacteraemia 30.27 19.03 12 15327 1329 56275399
Stenotrophomonas infection 30.23 19.03 13 15326 1768 56274960
Agranulocytosis 30.20 19.03 34 15305 22625 56254103
Hypertensive heart disease 29.76 19.03 14 15325 2349 56274379
Toxic skin eruption 29.62 19.03 25 15314 11714 56265014
White blood cell count decreased 29.26 19.03 88 15251 125902 56150826
Dysbiosis 29.02 19.03 10 15329 747 56275981
Hypersensitivity 28.93 19.03 17 15322 256391 56020337
Eosinophilic pneumonia 28.93 19.03 13 15326 1964 56274764
Leukocytosis 28.85 19.03 34 15305 23757 56252971
Neutropenic colitis 27.78 19.03 14 15325 2729 56273999
Klebsiella bacteraemia 26.09 19.03 11 15328 1425 56275303
Acute graft versus host disease in skin 25.73 19.03 14 15325 3188 56273540
Eosinophilia 24.86 19.03 29 15310 20048 56256680
Graft versus host disease 24.83 19.03 18 15321 6763 56269965
Musculoskeletal stiffness 24.81 19.03 6 15333 156001 56120727
Chemotherapeutic drug level increased 24.35 19.03 6 15333 135 56276593
Hyperbilirubinaemia 24.20 19.03 21 15318 10214 56266514
Leukopenia 24.02 19.03 57 15282 70883 56205845
Metabolic acidosis 23.91 19.03 41 15298 40413 56236315
Aphasia 23.73 19.03 35 15304 30380 56246348
Staphylococcal infection 23.39 19.03 39 15300 37579 56239149
Hyperoxaluria 23.20 19.03 6 15333 165 56276563
Engraft failure 23.07 19.03 7 15332 348 56276380
Product use issue 22.94 19.03 11 15328 186030 56090698
Gait disturbance 22.82 19.03 8 15331 163313 56113415
Cholestasis 22.50 19.03 32 15307 26881 56249847
Disseminated intravascular coagulation 22.42 19.03 26 15313 17859 56258869
Weight increased 22.22 19.03 18 15321 229685 56047043
Candida infection 22.17 19.03 31 15308 25636 56251092
Cytomegalovirus viraemia 22.03 19.03 15 15324 5105 56271623
Fall 21.92 19.03 40 15299 357470 55919258
Acute myeloid leukaemia 21.83 19.03 25 15314 16947 56259781
Thrombotic microangiopathy 21.63 19.03 19 15320 9392 56267336
Hypoaesthesia 21.43 19.03 6 15333 141485 56135243
Pseudomembranous colitis 21.43 19.03 12 15327 2891 56273837
Blood bilirubin increased 21.30 19.03 35 15304 33319 56243409
Delirium 21.18 19.03 40 15299 42477 56234251
Vascular device infection 20.84 19.03 15 15324 5575 56271153
Asthma 20.77 19.03 3 15336 112767 56163961
Ileus 20.53 19.03 22 15317 13860 56262868
Enterococcal sepsis 20.28 19.03 9 15330 1321 56275407
Respiratory alkalosis 20.08 19.03 11 15328 2540 56274188
Pericarditis 19.83 19.03 3 15336 108920 56167808
Tonsillitis bacterial 19.82 19.03 5 15334 124 56276604
Laryngeal inflammation 19.53 19.03 5 15334 132 56276596
Angiokeratoma 19.38 19.03 5 15334 136 56276592
Eosinophilic pneumonia acute 19.22 19.03 6 15333 328 56276400
Pleural effusion 19.17 19.03 59 15280 85421 56191307
Venoocclusive liver disease 19.13 19.03 13 15326 4408 56272320
Lower respiratory tract infection 19.08 19.03 4 15335 114790 56161938
Electrocardiogram T wave alternans 19.08 19.03 4 15335 42 56276686

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 257.45 16.13 349 19670 121500 31555825
Encephalopathy 234.30 16.13 181 19838 32293 31645032
Acute kidney injury 214.50 16.13 514 19505 279200 31398125
Cytokine release syndrome 166.15 16.13 113 19906 16529 31660796
Neurotoxicity 161.57 16.13 110 19909 16116 31661209
Septic shock 115.01 16.13 173 19846 65985 31611340
Drug reaction with eosinophilia and systemic symptoms 106.12 16.13 112 19907 29906 31647419
Pyrexia 101.41 16.13 419 19600 303421 31373904
Multiple organ dysfunction syndrome 101.40 16.13 166 19853 68037 31609288
Respiratory failure 95.66 16.13 203 19816 101246 31576079
Fatigue 79.20 16.13 58 19961 335148 31342177
Acute generalised exanthematous pustulosis 74.89 16.13 47 19972 5993 31671332
Renal tubular necrosis 74.56 16.13 67 19952 14692 31662633
Sepsis 73.75 16.13 237 19782 151692 31525633
Clostridium difficile colitis 73.36 16.13 65 19954 13991 31663334
Pathogen resistance 72.67 16.13 53 19966 8648 31668677
Hypoxia 71.43 16.13 120 19899 50193 31627132
Tubulointerstitial nephritis 68.90 16.13 71 19948 18425 31658900
Immune effector cell-associated neurotoxicity syndrome 66.15 16.13 32 19987 2447 31674878
Myoclonus 63.83 16.13 60 19959 13930 31663395
Neutrophil count decreased 63.66 16.13 109 19910 46285 31631040
Mental status changes 60.93 16.13 93 19926 35875 31641450
Methaemoglobinaemia 57.50 16.13 31 19988 2975 31674350
Dizziness 55.95 16.13 28 19991 199119 31478206
Neutropenia 55.85 16.13 205 19814 140159 31537166
Enterococcal infection 55.02 16.13 45 19974 8686 31668639
Product dose omission issue 51.53 16.13 4 20015 105582 31571743
Disseminated intravascular coagulation 46.47 16.13 61 19958 20476 31656849
Death 45.84 16.13 100 19919 360469 31316856
Bacteraemia 44.02 16.13 55 19964 17579 31659746
Brain herniation 43.36 16.13 28 19991 3749 31673576
Pseudomonas infection 42.88 16.13 44 19975 11357 31665968
Meningitis candida 42.81 16.13 10 20009 71 31677254
Septic embolus 40.84 16.13 18 20001 1111 31676214
Status epilepticus 40.68 16.13 44 19975 12062 31665263
Haemodialysis 40.03 16.13 40 19979 10005 31667320
Nephropathy toxic 39.45 16.13 42 19977 11311 31666014
Myocardial infarction 38.30 16.13 12 20007 113442 31563883
Drug resistance 37.40 16.13 59 19960 23394 31653931
Fall 36.78 16.13 38 19981 186051 31491274
Bronchopulmonary aspergillosis 36.41 16.13 44 19975 13590 31663735
Platelet count decreased 35.55 16.13 151 19868 110284 31567041
Thrombocytopenia 35.51 16.13 181 19838 142566 31534759
Botulism 35.45 16.13 10 20009 160 31677165
Glomerulosclerosis 34.25 16.13 14 20005 716 31676609
Acute respiratory distress syndrome 34.09 16.13 58 19961 24482 31652843
Blood culture positive 33.91 16.13 26 19993 4572 31672753
Arthralgia 33.36 16.13 28 19991 151396 31525929
Systemic candida 32.64 16.13 22 19997 3164 31674161
Clostridium difficile infection 32.58 16.13 47 19972 17232 31660093
White blood cell count decreased 32.49 16.13 125 19894 87273 31590052
Confusional state 32.42 16.13 168 19851 133166 31544159
Immune thrombocytopenia 32.32 16.13 33 19986 8465 31668860
Aspergillus infection 32.09 16.13 38 19981 11490 31665835
Antibiotic level above therapeutic 31.88 16.13 10 20009 234 31677091
Depression 31.75 16.13 9 20010 90806 31586519
Eosinophilia 31.04 16.13 54 19965 23199 31654126
Klebsiella infection 30.96 16.13 31 19988 7772 31669553
Uraemic encephalopathy 30.67 16.13 10 20009 266 31677059
Aspartate aminotransferase increased 30.47 16.13 98 19921 62621 31614704
Pain 29.72 16.13 45 19974 186714 31490611
Pneumonia 28.51 16.13 330 19689 334982 31342343
Cytomegalovirus enterocolitis 28.32 16.13 13 20006 883 31676442
Mucormycosis 27.56 16.13 25 19994 5545 31671780
Candida infection 27.46 16.13 42 19977 16216 31661109
Malaise 27.39 16.13 40 19979 168471 31508854
Enterocolitis 27.22 16.13 28 19991 7246 31670079
Insomnia 27.09 16.13 13 20006 94823 31582502
Burkholderia test positive 26.69 16.13 13 20006 1009 31676316
Metabolic encephalopathy 26.53 16.13 21 19998 3868 31673457
Gait disturbance 26.50 16.13 8 20011 77487 31599838
Weight decreased 25.97 16.13 38 19981 159914 31517411
Pneumonia bacterial 25.51 16.13 32 19987 10264 31667061
Disseminated mucormycosis 25.43 16.13 10 20009 462 31676863
Cytomegalovirus viraemia 25.37 16.13 26 19993 6699 31670626
Pleural effusion 25.30 16.13 104 19915 74816 31602509
Transaminases increased 24.37 16.13 50 19969 24291 31653034
Dyspnoea 24.36 16.13 123 19896 343356 31333969
Blood pressure increased 24.18 16.13 10 20009 79623 31597702
Respiratory distress 23.68 16.13 60 19959 33493 31643832
Rash morbilliform 23.63 16.13 17 20002 2714 31674611
Acute myeloid leukaemia recurrent 23.57 16.13 15 20004 1959 31675366
Joint swelling 23.51 16.13 3 20016 53428 31623897
Alanine aminotransferase increased 23.16 16.13 101 19918 74555 31602770
Bacterial toxaemia 23.08 16.13 7 20012 146 31677179
Choluria 22.77 16.13 7 20012 153 31677172
Aeromonas infection 22.59 16.13 8 20011 275 31677050
Cytokine storm 22.58 16.13 10 20009 624 31676701
Toxic encephalopathy 22.50 16.13 21 19998 4829 31672496
Anxiety 22.38 16.13 15 20004 91018 31586307
Inappropriate schedule of product administration 22.01 16.13 3 20016 50820 31626505
Trichosporon infection 21.67 16.13 10 20009 687 31676638
Corynebacterium infection 21.19 16.13 9 20010 507 31676818
Feeling abnormal 21.15 16.13 5 20014 56997 31620328
Cholestasis 21.09 16.13 48 19971 25027 31652298
Hypersensitivity vasculitis 20.88 16.13 17 20002 3258 31674067
Headache 20.80 16.13 54 19965 183598 31493727
Blood creatinine increased 20.77 16.13 111 19908 88967 31588358
Renal failure 20.67 16.13 141 19878 123189 31554136
Toxic epidermal necrolysis 20.61 16.13 41 19978 19483 31657842
Drug intolerance 20.46 16.13 4 20015 52029 31625296
Kidney fibrosis 20.26 16.13 14 20005 2096 31675229
Organising pneumonia 20.24 16.13 21 19998 5489 31671836
Cerebral aspergillosis 20.20 16.13 12 20007 1386 31675939
Off label use 20.08 16.13 319 19700 346955 31330370
Peripheral swelling 19.84 16.13 9 20010 67856 31609469
Fungal infection 19.69 16.13 34 19985 14517 31662808
Vanishing bile duct syndrome 19.59 16.13 9 20010 612 31676713
Hospitalisation 19.23 16.13 4 20015 49803 31627522
Asthenia 19.21 16.13 75 19944 224680 31452645
Procalcitonin increased 18.22 16.13 12 20007 1661 31675664
Haemophagocytic lymphohistiocytosis 18.09 16.13 29 19990 11649 31665676
Disseminated cryptococcosis 17.91 16.13 11 20008 1349 31675976
Aphasia 17.71 16.13 39 19980 19892 31657433
Flavobacterium infection 17.67 16.13 5 20014 81 31677244
Sputum culture positive 17.66 16.13 12 20007 1749 31675576
Acute respiratory failure 17.58 16.13 48 19971 28007 31649318
Retinal ischaemia 17.57 16.13 7 20012 335 31676990
Lactobacillus infection 17.53 16.13 6 20013 186 31677139
Enterobacter infection 17.46 16.13 13 20006 2187 31675138
Drug level increased 17.37 16.13 39 19980 20147 31657178
Acute lymphocytic leukaemia recurrent 17.21 16.13 15 20004 3155 31674170
Systemic mycosis 17.20 16.13 11 20008 1448 31675877
Eye infection fungal 17.20 16.13 7 20012 354 31676971
Pancytopenia 17.18 16.13 104 19915 87212 31590113
Hepatosplenic candidiasis 16.84 16.13 6 20013 210 31677115
Delirium 16.84 16.13 61 19958 41360 31635965
Vascular device infection 16.64 16.13 15 20004 3300 31674025
Musculoskeletal stiffness 16.62 16.13 3 20016 41322 31636003
Dysbiosis 16.42 16.13 7 20012 398 31676927
Foetal exposure during pregnancy 16.37 16.13 3 20016 40873 31636452
Adenoviral haemorrhagic cystitis 16.27 16.13 7 20012 407 31676918
Hypotension 16.26 16.13 199 19820 204419 31472906
Hypercapnia 16.16 16.13 16 20003 3955 31673370

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 568.67 16.13 583 32713 203735 70691413
Encephalopathy 565.43 16.13 355 32941 61306 70833842
Acute kidney injury 470.11 16.13 815 32481 473809 70421339
Neurotoxicity 362.43 16.13 206 33090 29620 70865528
Cytokine release syndrome 311.36 16.13 179 33117 26288 70868860
Drug reaction with eosinophilia and systemic symptoms 234.50 16.13 204 33092 57809 70837339
Septic shock 211.55 16.13 262 33034 111996 70783152
Pyrexia 205.02 16.13 687 32609 606265 70288883
Status epilepticus 201.72 16.13 132 33164 24394 70870754
Sepsis 195.56 16.13 384 32912 244161 70650987
Multiple organ dysfunction syndrome 189.73 16.13 244 33052 108271 70786877
Myoclonus 181.32 16.13 127 33169 26228 70868920
Respiratory failure 170.17 16.13 293 33003 168442 70726706
Mental status changes 155.21 16.13 169 33127 62932 70832216
Tubulointerstitial nephritis 147.26 16.13 123 33173 32953 70862195
Thrombocytopenia 141.01 16.13 332 32964 238778 70656370
Renal tubular necrosis 135.07 16.13 101 33195 23070 70872078
Fatigue 131.12 16.13 117 33179 824202 70070946
Pain 128.14 16.13 68 33228 628748 70266400
Immune effector cell-associated neurotoxicity syndrome 122.89 16.13 52 33244 3926 70891222
Neutrophil count decreased 120.26 16.13 171 33125 83385 70811763
Hypoxia 119.84 16.13 181 33115 93163 70801985
Clostridium difficile colitis 117.16 16.13 102 33194 28894 70866254
Rheumatoid arthritis 115.69 16.13 5 33291 291800 70603348
Arthralgia 115.58 16.13 46 33250 503344 70391804
Pathogen resistance 112.92 16.13 73 33223 13206 70881942
Neutropenia 109.38 16.13 316 32980 256840 70638308
Acute generalised exanthematous pustulosis 107.76 16.13 75 33221 15322 70879826
Platelet count decreased 101.22 16.13 244 33052 177978 70717170
Pneumonia 99.82 16.13 546 32750 595686 70299462
Joint swelling 98.22 16.13 5 33291 253206 70641942
Dizziness 97.71 16.13 48 33248 464093 70431055
Drug resistance 96.88 16.13 104 33192 38086 70857062
Toxic encephalopathy 92.92 16.13 59 33237 10347 70884801
Klebsiella infection 89.37 16.13 65 33231 14227 70880921
Enterococcal infection 85.96 16.13 64 33232 14518 70880630
Bacteraemia 83.62 16.13 85 33211 29224 70865924
Headache 77.84 16.13 95 33201 580310 70314838
Product dose omission issue 76.46 16.13 7 33289 217461 70677687
Malaise 74.09 16.13 57 33239 432875 70462273
Nephropathy toxic 70.53 16.13 63 33233 18451 70876697
Drug intolerance 70.17 16.13 11 33285 225676 70669472
Acute respiratory distress syndrome 69.25 16.13 91 33205 41163 70853985
Disseminated intravascular coagulation 65.74 16.13 80 33216 33518 70861630
Alopecia 65.65 16.13 8 33288 198482 70696666
Nasopharyngitis 62.32 16.13 14 33282 222192 70672956
Pseudomonas infection 61.44 16.13 59 33237 18935 70876213
Clostridium difficile infection 61.13 16.13 83 33213 38733 70856415
White blood cell count decreased 60.93 16.13 197 33099 169944 70725204
Aspartate aminotransferase increased 60.74 16.13 163 33133 126815 70768333
Fall 60.21 16.13 72 33224 444024 70451124
Peripheral swelling 58.63 16.13 19 33277 236544 70658604
Bronchopulmonary aspergillosis 58.25 16.13 60 33236 20942 70874206
Arthropathy 58.04 16.13 3 33293 150054 70745094
Methaemoglobinaemia 57.93 16.13 33 33263 4753 70890395
Confusional state 57.53 16.13 275 33021 284123 70611025
Renal failure 57.26 16.13 207 33089 188863 70706285
Brain herniation 56.10 16.13 37 33259 6919 70888229
Mucormycosis 55.99 16.13 39 33257 7975 70887173
Antibiotic level above therapeutic 55.89 16.13 18 33278 625 70894523
Blood creatinine increased 54.32 16.13 169 33127 142832 70752316
Abdominal discomfort 53.62 16.13 17 33279 214641 70680507
Pancytopenia 53.23 16.13 174 33122 150933 70744215
Trichosporon infection 52.53 16.13 19 33277 942 70894206
Metabolic encephalopathy 52.20 16.13 38 33258 8325 70886823
Eosinophilia 51.44 16.13 78 33218 40241 70854907
Haemodialysis 50.69 16.13 51 33245 17315 70877833
Weight decreased 50.42 16.13 43 33253 310445 70584703
Respiratory distress 47.42 16.13 89 33207 54561 70840587
Pleural effusion 46.79 16.13 153 33143 132711 70762437
Septic embolus 46.66 16.13 21 33275 1839 70893309
Gait disturbance 45.62 16.13 15 33281 185091 70710057
Toxic epidermal necrolysis 45.55 16.13 73 33223 39484 70855664
Dyspnoea 45.32 16.13 197 33099 769863 70125285
Alanine aminotransferase increased 45.08 16.13 162 33134 147318 70747830
Acute respiratory failure 43.62 16.13 85 33211 53580 70841568
Hypotension 42.61 16.13 330 32966 404051 70491097
Pain in extremity 42.53 16.13 55 33241 328027 70567121
Musculoskeletal stiffness 42.04 16.13 9 33287 147751 70747397
Candida infection 41.60 16.13 65 33231 34408 70860740
Cholestasis 41.58 16.13 78 33218 47794 70847354
Depression 41.14 16.13 21 33275 198953 70696195
Fungaemia 41.14 16.13 25 33271 4057 70891091
Neutropenic colitis 40.75 16.13 27 33269 5087 70890061
Cholestatic liver injury 40.66 16.13 25 33271 4143 70891005
Agranulocytosis 40.55 16.13 70 33226 40228 70854920
Myocardial infarction 40.42 16.13 15 33281 171630 70723518
Meningitis candida 40.04 16.13 10 33286 134 70895014
Differentiation syndrome 39.91 16.13 20 33276 2227 70892921
Systemic candida 39.41 16.13 28 33268 5906 70889242
Enterocolitis 39.29 16.13 39 33257 13027 70882121
Cytomegalovirus viraemia 39.13 16.13 37 33259 11648 70883500
Blood bilirubin increased 38.31 16.13 86 33210 59815 70835333
Insomnia 38.06 16.13 28 33268 217778 70677370
Blood pressure increased 37.36 16.13 21 33275 188496 70706652
Asthma 37.27 16.13 6 33290 120787 70774361
Delirium 36.89 16.13 97 33199 74517 70820631
Staphylococcal infection 35.65 16.13 78 33218 53326 70841822
Hypoaesthesia 35.26 16.13 14 33282 153725 70741423
Renal impairment 34.93 16.13 147 33149 143790 70751358
Off label use 34.89 16.13 515 32781 742545 70152603
Pneumonia bacterial 34.80 16.13 41 33255 16600 70878548
Nausea 34.77 16.13 246 33050 851842 70043306
Weight increased 34.18 16.13 38 33258 242293 70652855
Haemophagocytic lymphohistiocytosis 34.05 16.13 44 33252 19568 70875580
Vascular device infection 33.95 16.13 29 33267 8001 70887147
Aphasia 33.33 16.13 67 33229 43182 70851966
Blood culture positive 32.24 16.13 28 33268 7898 70887250
Immune thrombocytopenia 32.14 16.13 39 33257 16285 70878863
Cytomegalovirus enterocolitis 31.75 16.13 15 33281 1468 70893680
Liver abscess 31.72 16.13 24 33272 5575 70889573
Leukocytosis 31.23 16.13 62 33234 39606 70855542
Drug level increased 31.15 16.13 59 33237 36410 70858738
Feeling abnormal 30.97 16.13 14 33282 142305 70752843
Glomerulosclerosis 30.94 16.13 13 33283 964 70894184
Aspergillus infection 30.89 16.13 40 33256 17828 70877320
Enterococcal bacteraemia 30.87 16.13 18 33278 2708 70892440
Pulmonary haemorrhage 30.80 16.13 35 33261 13638 70881510
Sinusitis 30.54 16.13 21 33275 169174 70725974
Botulism 30.52 16.13 10 33286 367 70894781
Hepatic function abnormal 30.21 16.13 85 33211 67911 70827237
Rash morbilliform 30.06 16.13 23 33273 5432 70889716
Arthritis 29.93 16.13 5 33291 97975 70797173
Injection site pain 29.92 16.13 9 33287 117610 70777538
Uraemic encephalopathy 29.71 16.13 11 33285 583 70894565
Lower respiratory tract infection 29.51 16.13 8 33288 111905 70783243
Swelling 29.51 16.13 27 33269 188512 70706636
Rash maculo-papular 29.49 16.13 70 33226 50475 70844673
Mixed liver injury 29.39 16.13 24 33272 6225 70888923
Muscle spasms 29.33 16.13 18 33278 154028 70741120
Hypersensitivity 29.27 16.13 39 33257 229773 70665375
Enterococcal sepsis 29.27 16.13 17 33279 2540 70892608
Balance disorder 28.90 16.13 4 33292 90124 70805024
Discomfort 28.83 16.13 7 33289 105429 70789719
Tumour lysis syndrome 28.20 16.13 42 33254 21318 70873830
Cytomegalovirus test positive 27.70 16.13 22 33274 5486 70889662
Systemic lupus erythematosus 27.41 16.13 7 33289 101895 70793253
Shock 26.93 16.13 59 33237 40366 70854782
Intentional product misuse 26.82 16.13 3 33293 79592 70815556
Enterobacter infection 26.60 16.13 19 33277 4041 70891107
Acute myeloid leukaemia 26.35 16.13 50 33246 30890 70864258
Anxiety 25.49 16.13 40 33256 220290 70674858
Transaminases increased 25.17 16.13 63 33233 46955 70848193
Nephritis allergic 25.16 16.13 10 33286 643 70894505
Disseminated mucormycosis 25.16 16.13 10 33286 643 70894505
Lung infiltration 25.02 16.13 40 33256 21584 70873564
Encephalitis Japanese B 24.95 16.13 6 33290 68 70895080
Gastrooesophageal reflux disease 24.90 16.13 6 33290 90833 70804315
Bacterial toxaemia 24.69 16.13 7 33289 156 70894992
Drug eruption 24.46 16.13 56 33240 39440 70855708
Unresponsive to stimuli 24.14 16.13 66 33230 51865 70843283
Paraesthesia 23.79 16.13 20 33276 145517 70749631
Device related infection 23.78 16.13 49 33247 32136 70863012
Back pain 23.77 16.13 58 33238 271094 70624054
Serum ferritin increased 23.67 16.13 25 33271 8980 70886168
Disseminated cryptococcosis 23.47 16.13 13 33283 1774 70893374
Activated partial thromboplastin time prolonged 22.98 16.13 30 33266 13475 70881673
Contusion 22.96 16.13 16 33280 128020 70767128
Leukopenia 22.92 16.13 105 33191 106455 70788693
Corynebacterium infection 22.89 16.13 11 33285 1118 70894030
Aeromonas infection 22.81 16.13 8 33288 362 70894786
Pseudomembranous colitis 22.72 16.13 19 33277 5092 70890056
Burkholderia test positive 22.70 16.13 9 33287 575 70894573
Graft versus host disease 21.96 16.13 31 33265 14992 70880156
Venoocclusive liver disease 21.82 16.13 26 33270 10652 70884496
Systemic mycosis 21.77 16.13 14 33282 2508 70892640
Engraftment syndrome 21.71 16.13 11 33285 1253 70893895
Acidosis 21.43 16.13 34 33262 18229 70876919
Acute lymphocytic leukaemia recurrent 21.32 16.13 18 33278 4886 70890262
Procalcitonin increased 21.30 16.13 14 33282 2602 70892546
Small intestinal obstruction 21.19 16.13 40 33256 24615 70870533
Klebsiella bacteraemia 21.12 16.13 14 33282 2640 70892508
Chest pain 21.05 16.13 55 33241 251205 70643943
Blood urea increased 20.99 16.13 58 33238 45851 70849297
Cerebral aspergillosis 20.96 16.13 12 33284 1744 70893404
Vanishing bile duct syndrome 20.96 16.13 11 33285 1348 70893800
Asthenia 20.67 16.13 128 33168 457538 70437610
Dry mouth 20.64 16.13 4 33292 70453 70824695
Dyspepsia 20.60 16.13 8 33288 89069 70806079
Escherichia bacteraemia 20.45 16.13 19 33277 5850 70889298
Pulseless electrical activity 20.41 16.13 28 33268 13187 70881961
Blood cholesterol increased 20.40 16.13 3 33293 64601 70830547
Heparin-induced thrombocytopenia 20.13 16.13 23 33273 9014 70886134
Osteoarthritis 20.12 16.13 5 33291 74142 70821006
Clostridial infection 20.03 16.13 18 33278 5311 70889837
Respiratory alkalosis 19.95 16.13 16 33280 4045 70891103
Abdominal pain upper 19.79 16.13 38 33258 193564 70701584
Organising pneumonia 19.77 16.13 24 33272 10026 70885122
Blastomycosis 19.76 16.13 8 33288 540 70894608
Vertigo 19.57 16.13 3 33293 62640 70832508
Mediastinitis 19.46 16.13 9 33287 839 70894309
Chemotherapeutic drug level increased 19.37 16.13 7 33289 346 70894802
Choluria 19.31 16.13 7 33289 349 70894799
Tachypnoea 19.30 16.13 42 33254 28596 70866552
Chest discomfort 19.23 16.13 18 33278 124363 70770785
Laryngeal inflammation 19.07 16.13 6 33290 193 70894955
Loss of personal independence in daily activities 19.03 16.13 8 33288 84902 70810246
Pericarditis 18.95 16.13 8 33288 84697 70810451
Product contamination microbial 18.92 16.13 9 33287 895 70894253
Memory impairment 18.81 16.13 10 33286 92631 70802517
Cardiac arrest 18.80 16.13 134 33162 159700 70735448
Cytokine storm 18.66 16.13 9 33287 922 70894226
Hyperbilirubinaemia 18.64 16.13 36 33260 22532 70872616
Enterobacter bacteraemia 18.59 16.13 8 33288 629 70894519
Systemic inflammatory response syndrome 18.54 16.13 24 33272 10688 70884460
Hypertensive heart disease 18.33 16.13 15 33281 3901 70891247
Flavobacterium infection 18.24 16.13 5 33291 98 70895050
Hypervolaemia 17.99 16.13 50 33246 39656 70855492
Staphylococcal bacteraemia 17.90 16.13 24 33272 11058 70884090
Injection site erythema 17.80 16.13 6 33290 72918 70822230
Blood lactate dehydrogenase increased 17.69 16.13 46 33250 35081 70860067
Hypoalbuminaemia 17.66 16.13 32 33264 19090 70876058
Pneumonitis 17.54 16.13 61 33235 54536 70840612
Drug-induced liver injury 17.43 16.13 62 33234 56051 70839097
Eye infection fungal 17.31 16.13 7 33289 471 70894677
Inappropriate schedule of product administration 17.30 16.13 15 33281 107540 70787608
Coagulopathy 17.22 16.13 44 33252 33205 70861943
Dialysis 17.20 16.13 30 33266 17372 70877776
Ureaplasma infection 17.12 16.13 8 33288 764 70894384
COVID-19 pneumonia 16.88 16.13 34 33262 21935 70873213
Therapeutic product effect incomplete 16.67 16.13 19 33277 119863 70775285
Hypercapnia 16.56 16.13 20 33276 8309 70886839
Flushing 16.49 16.13 9 33287 82163 70812985
Death 16.28 16.13 157 33139 509904 70385244
Mucosal inflammation 16.21 16.13 69 33227 67781 70827367
Kidney fibrosis 16.21 16.13 13 33283 3287 70891861

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DE01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Fourth-generation cephalosporins
ATC J01RA06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection due to Pseudomonas aeruginosa indication 11218009
Pneumonia due to Streptococcus indication 34020007
Pneumonia due to Pseudomonas indication 41381004
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Infectious disease of abdomen indication 128070006
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Bacterial peritonitis indication 197171003
Pneumococcal pneumonia indication 233607000
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infection due to Staphylococcus aureus indication 406602003
Urinary tract infection caused by Klebsiella indication 369001000119100
Complicated Proteus UTI indication
E. Coli Pyelonephritis indication
Complicated Urinary Tract Infections indication
Complicated Bacteroides Peritonitis indication
Complicated Streptococcus Peritonitis indication
Klebsiella Pyelonephritis indication
Complicated E. Coli Peritonitis indication
Enterobacter Pneumonia indication
Complicated Klebsiella Peritonitis indication
Proteus Pyelonephritis indication
Myoclonus contraindication 17450006
Colitis contraindication 64226004 DOID:0060180
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Disorder of brain contraindication 81308009 DOID:936
Seizure disorder contraindication 128613002
Impaired renal function disorder contraindication 197663003
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.32 acidic
pKa2 13.31 acidic
pKa3 3.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4024049 VUID
N0000022054 NUI
D01157 KEGG_DRUG
123171-59-5 SECONDARY_CAS_RN
20481 RXNORM
4020908 VANDF
4024049 VANDF
C0055003 UMLSCUI
CHEBI:478164 CHEBI
9WT PDB_CHEM_ID
CHEMBL186 ChEMBL_ID
CHEMBL1200962 ChEMBL_ID
D000077723 MESH_DESCRIPTOR_UI
DB01413 DRUGBANK_ID
10772 IUPHAR_LIGAND_ID
6092 INN_ID
807PW4VQE3 UNII
5479537 PUBCHEM_CID
116681 MMSL
4373 MMSL
d03882 MMSL
004974 NDDF
004975 NDDF
370370003 SNOMEDCT_US
370371004 SNOMEDCT_US
96048006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CEFEPIME HYDROCHLORIDE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3193 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 30 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3193 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 30 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3195 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 30 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3195 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 30 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0338-1301 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0338-1301 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0338-1301 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0409-9566 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0409-9735 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
Cefepime Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-3222 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-3223 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-121 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 29 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-121 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 29 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-122 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 29 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-122 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 29 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-130 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-131 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-240 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-241 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6144 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6144 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6145 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6145 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6146 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6146 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6147 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6147 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6245 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6246 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 63323-326 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections